Table 3

VIP trial results by absence or presence of classic neovascular lesions

Outcome at 2 years (primary outcome of loss of at least 15 letters of VA)VIP PDT groupVIP PlaceboVIP RR (95% CI)TAP PDT groupTAP PlaceboTAP RR (95% CI)
*As reported in published paper.
†Mostly >0% and <50% according to table of participants.
‡Not reported; calculated by subtraction.
§Minimally classic TAP trial results.
Whole trial*121/22576/1140.81 (0.68 to 0.96)189/402129/2070.75 (0.65 to 0.88)
No classic*91/16663/920.80 (0.66 to 0.97)18/4114/200.63 (0.40 to 0.98)
>0% classic†30/59‡13/22‡0.86 (0.56 to 1.32)106/202§58/104§0.94 (0.76 to 1.17) §